
|Videos|October 20, 2021
AMCP Nexus 2021: Cate Lockhart of Biologics and Biosimilars Collective Intelligence Consortium Discusses Biosimilars Such as Semglee and the Current Standing of Biosimilars, PBMs
Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5






















